替米沙坦治疗轻中度高血压患者降压效果及其安全性

目的:观察替米沙坦治疗轻、中度高血压病的临床降压效果。方法:72例临床确诊为轻、中度高血压病者,随机分为替米沙坦组(35人)和氯沙坦组(37人),分别每日早晨服替米沙坦80mg,或氯沙坦50mg,总观察时间为8周。服药后第4、8周测定血压,入选时与服药后第8周测定血钾、肝功能、肾功能。结果:服药第4周、第8周两观察组血压均较观察前显著降低(P<0.05,P<0.01),且替米沙坦的降压作用较氯沙坦明显(P<0.01,P<0.001)。到第8周末,替米沙坦组与氯沙坦组降压总有效率分别达94.1%与88.6%。与观察开始前比较,第8周末血钾、肝功能、肾功能无明显改变。结论:替米沙坦对轻、中度高血压病患者有良好的降压效果,服用安全。

Therapeutic effects of telmisartan on patients with mild-to-moderate essential hypertension and its safety

Objective: To evaluate the therapeutic effects of telmisartan on patients with mild-to-moderate essential hypertension. Methods: Seventy-two patients with essential hypertension were enrolled in this clinical pharmacological trial and randomly divided into telmisartan group (35 patients) and losartan group (37 patients). In the evaluating period of 8 weeks,every patients in telmisartan group took 80 mg of telmisartan and the patients in losartan group took 50 mg of losartan every morning. Their blood pressure was measured after 4 and 8 weeks of treatment. The serum level of potassium, liver function and renal function were examined before and after the trial. Results:The blood pressures of both groups were decreased significantly after 4 and 8 weeks of trial compared with those before the trial (P<0.05, P<0.01). The blood pressures of telmisartan group were decreased more remarkably than losartan group (P<0.01,P<0.001). The antihypertensive efficacy rates of telmisartan group and losartan group were 94.1% and 88.6%,respectively. The serum level of potassium, liver function and renal function had no obvious difference before and after the trial. Conclusion: Telmisartan can be used effectively and safely in anti-hypertensive medication of patients with mild-to-moderate essential hypertension.